Tag: KDC-MN-082

  • Semaglutide

    GLP-1 receptor agonist (long-acting)

    A long-acting GLP-1 receptor agonist FDA-approved as Ozempic (T2DM) and Wegovy (obesity), with extended duration through albumin-binding and amino acid substitution.

    Abstract

    Semaglutide (Ozempic, Wegovy, Rybelsus; CAS 910463-68-2; molecular weight 4113.58) is a long-acting GLP-1 receptor agonist developed by Novo Nordisk and approved for type 2 diabetes (Ozempic, 2017; Rybelsus oral, 2019) and chronic weight management (Wegovy, 2021). The compound is structurally based on native GLP-1 with two amino acid substitutions (Aib at position 8 to resist DPP-4 cleavage; Arg34Lys) and a fatty acid chain (octadecanoic diacid) attached via a glutamic acid spacer that enables reversible albumin binding for extended plasma half-life (approximately 1 week). Mechanism is GLP-1 receptor agonism producing glucose-dependent insulin release, glucagon suppression, gastric emptying delay, and central satiety effects. The semaglutide STEP program demonstrated 14 to 18 percent weight loss over 68 weeks in obesity trials; cardiovascular outcomes trials demonstrated MACE reduction in T2DM. Schedule status: prescription-only.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.